Holen Sie sich die Stockscreener-App
4.16
3.74%
0.15
Handel nachbörslich:
4.20
0.04
+0.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.01
Offen:
$3.95
24-Stunden-Volumen:
779.31K
Relative Volume:
2.58
Marktkapitalisierung:
$166.21M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-0.6735
EPS:
-6.1766
Netto-Cashflow:
$-91.73M
1W Leistung:
-15.27%
1M Leistung:
-16.13%
6M Leistung:
-33.97%
1J Leistung:
-15.79%
1-Tages-Spanne:
$3.90
$4.33
1-Wochen-Bereich:
$3.90
$4.9411
52-Wochen-Spanne:
$3.90
$15.05
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Vergleichen Sie SLDB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
4.16 | 166.21M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
The Manufacturers Life Insurance Company Buys New Shares in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences stock hits 52-week low at $4.61 - Investing.com
Wedbush Initiates Coverage on Solid Biosciences (NASDAQ:SLDB) - Defense World
Solid Biosciences’ (SLDB) Buy Rating Reiterated at HC Wainwright - Defense World
Solid Biosciences (NASDAQ:SLDB) Upgraded at Wedbush - Defense World
Wedbush Initiates Coverage of Solid Biosciences (SLDB) with Outperform Recommendation - MSN
Solid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Wedbush - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Coverage Initiated by Analysts at Wedbush - MarketBeat
Solid Biosciences' SWOT analysis: gene therapy stock's potential in DMD treatment - Investing.com
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst - Yahoo Finance
Solid Biosciences (NASDAQ:SLDB) Upgraded at Citizens Jmp - Defense World
Solid Biosciences (NASDAQ:SLDB) Research Coverage Started at JMP Securities - Defense World
HC Wainwright Reiterates Buy Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences initiated with an Outperform at JMP Securities - MSN
Learn to Evaluate (SLDB) using the Charts - Stock Traders Daily
Solid Biosciences (NASDAQ:SLDB) Upgraded to Strong-Buy at Citizens Jmp - MarketBeat
JMP Securities Initiates Coverage of Solid Biosciences (SLDB) with Market Outperform Recommendation - MSN
Solid Biosciences stock a buy, says JMP—proprietary capsid tech adds partnership upside - Investing.com Canada
Solid Biosciences (NASDAQ:SLDB) Now Covered by Analysts at JMP Securities - MarketBeat
Point72 Asset Management L.P. Increases Position in Solid Biosciences Inc. (NASDAQ:SLDB) - MarketBeat
Solid Biosciences secures licenses for cardiac gene therapy By Investing.com - Investing.com Canada
Solid Biosciences CEO Alexander Cumbo sells $62,236 in stock By Investing.com - Investing.com Australia
Solid Biosciences CEO Alexander Cumbo sells $62,236 in stock - Investing.com India
Solid Biosciences executive sells shares worth $25,822 By Investing.com - Investing.com Nigeria
Solid Biosciences secures licenses for cardiac gene therapy - Investing.com India
Solid Biosciences' COO David Howton sells $28,396 in stock By Investing.com - Investing.com Nigeria
Solid Biosciences executive sells shares worth $25,822 - Investing.com
Solid Biosciences' COO David Howton sells $28,396 in stock - Investing.com India
Solid Biosciences Announces Collaboration with Mayo Clinic - GlobeNewswire
Solid Biosciences reports inducement grant under Nasdaq listing rule - Yahoo Finance
Solid Biosciences Lands Major Gene Therapy Deal with Mayo Clinic for Heart Disease Breakthroughs - StockTitan
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Analysts Set Solid Biosciences Inc. (NASDAQ:SLDB) Price Target at $15.14 - MarketBeat
(SLDB) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Vestal Point Capital LP Boosts Stake in Solid Biosciences Inc. (NASDAQ:SLDB) - MarketBeat
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Solid Biosciences to Present at Citi and Piper Sandler Healthcare Conferences | SLDB Stock News - StockTitan
Cantor Fitzgerald Brokers Reduce Earnings Estimates for SLDB - MarketBeat
Solid Biosciences Reports Increased Losses Amid R&D Focus - TipRanks
(SLDB) Investment Analysis - Stock Traders Daily
Litecoin Climbs 10% In Rally - Investing.com
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth? - Simply Wall St
Perceptive Advisors LLC's Strategic Acquisition in Solid Bioscie - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Solid Biosciences Inc. - GuruFocus.com
FY2024 Earnings Estimate for SLDB Issued By Chardan Capital - MarketBeat
Solid Biosciences to Present at the Jefferies London Healthcare Conference - GlobeNewswire
Solid Biosciences' SWOT analysis: DMD therapy stock faces pivotal moment - Investing.com India
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):